Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 729.06M +71.6% |
| Revenue (ttm) | n/a |
| Net Income | -210.71M |
| EPS | -3.43 |
| Shares Out | 64.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 810,429 |
| Open | 11.71 |
| Previous Close | 11.73 |
| Day's Range | 10.95 - 12.04 |
| 52-Week Range | 7.25 - 23.19 |
| Beta | -0.06 |
| Analysts | Strong Buy |
| Price Target | 34.70 (+208.99%) |
| Earnings Date | Nov 10, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $34.7, which is an increase of 208.99% from the latest price.
News
Cullinan Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
December CLN-978 data will cover multi-dose activity across SLE, RA and Sjögren’s, while Phase II planning advances. CLN-049 is recruiting in pivotal AML testing, and zipalertinib regulatory milestones and profit share support a cash runway into 2029.
Cullinan Therapeutics reports Q3 EPS (74c), consensus (84c)
“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertini...
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren's disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimm...
Cullinan Therapeutics Earnings release: Q3 2026
Cullinan Therapeutics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Cullinan Therapeutics Quarterly report: Q3 2026
Cullinan Therapeutics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, d...
Cullinan announces data from Genrix Bio Phase 1b/2a study of velinotamig
Cullinan Therapeutics (CGEM) announced clinical data from the ongoing Genrix Bio Phase 1b/2a study of velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus, ...
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses
Cullinan selloff due to response rates drop, says William Blair
William Blair says abstracts for the upcoming American Society of Hematology Annual Meeting were published, including updated data for Cullinan Therapeutics (CGEM)’ CLN-049 in relapsed/refractory acut...
Cullinan sinks after leukemia data abstract posts ahead of ASH
Cullinan Therapeutics (CGEM) shares are sinking after a data abstract for the company’s T cell engager program, CLN-049, was posted ahead of the American Society of Hematology Annual Meeting and…
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modif...
Cullinan Therapeutics price target raised to $41 from $40 at BTIG
BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $41 from $40 and keeps a Buy rating on the shares. The firm cites the company announcement of clearance…
Cullinan Therapeutics announces FDA clearance to initiate ITP, wAIHA trial
Cullinan Therapeutics (CGEM) announced that the FDA and Australian Therapeutic Goods Administration have granted clearance to initiate its global Phase 1b/2a clinical trial in adults with relapsing an...
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA
Cullinan: Zipalertinib demonstrates ‘clinically meaningful’ antitumor activity
Taiho Oncology and Cullinan Therapeutics (CGEM) announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-...
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluatin...
Cullinan Therapeutics doses first patient in CLN-049 trial
Cullinan Therapeutics (CGEM) announced that the first patient has been dosed in its Phase 2 study of CLN-049, an investigational FLT3 T cell engager, in patients with relapsed/refractory acute myeloid...
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, d...
Cullinan Therapeutics initiates NDA for Zipalertinib
The company stated: “Cullinan Therapeutics (CGEM) announced the initiation of a New Drug Application submission to the U.S. Food and Drug Administration for zipalertinib in combination with platinum-b...
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $35 from $30 and keeps a Buy rating on the shares. The company yesterday announced milestones across its…
Cullinan Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Multiple T cell engager programs are advancing, with a major December data update planned for CLN-978 across lupus, RA, and Sjögren's disease. Velinotamig is progressing in SLE and will expand into autoimmune cytopenias, while CLN-049 and zipalertinib are moving toward key regulatory milestones.
Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen
Cullinan Therapeutics (CGEM) enters Q4 with a catalyst-rich roadmap across its autoimmune and AML programs, as longer follow-up and multi-dose data for ‘978 in SLE, RA, and SjD could help…
Cullinan falls after pushing rheumatoid arthritis data to December
Shares of Cullinan Therapeutics (CGEM) after the company said CLN-978 data in systemic lupus erythematosus, difficult-to-treat rheumatoid arthritis, and Sjogren’s disease will be released in December....
Cullinan Therapeutics outlines Q4 2026 milestones across pipeline
Cullinan Therapeutics (CGEM) outlined fourth quarter 2026 milestones across its immunology and oncology pipeline. The Company plans to share the following immunology and oncology pipeline updates in Q...